Bobby is a Director of Healthcare Investments at Touchstone Innovations, a leading early stage life science venture fund in the UK. Prior to Innovations, Bobby was Investment Director of Novo Seeds, the early stage investment arm of Novo AS. He led investments there in several seed stage companies including Acesion, Avilex, RSPR Pharma, and Contera Pharma (exited).
He currently is on the board of Artios and Auspherix.
Bobby has 17 years’ experience in the life science industry including drug development (Maxygen), business development (LEO pharma) and venture capital investing.
Bobby obtained his PhD in Biology from University of Virginia/ Imperial College and his BS in Biochemistry at the University of Rochester.